ReNeuron Group plc
("ReNeuron" or "the Group" or the "Company")
Block listing application
ReNeuron Group plc (AIM: RENE), a UK-based leader in stem cell derived exosome technologies, announces that an application has been made to the London Stock Exchange for a block listing of securities in respect of 5,254,368 Ordinary Shares of 1p each (the "New Ordinary Shares") to be admitted to trading on AIM. It is expected that admission will become effective on or around 2 March 2023.
The New Ordinary Shares will be issued when necessary, in order to satisfy the issue of shares pursuant to the exercise of options issued under the Company's share schemes. When issued, the New Ordinary Shares will be credited as fully paid and will rank pari passu in all respects with the existing Ordinary Shares of 1p each in the capital of the Company.
ENDS
Enquiries:
| ReNeuron | ||
| Iain Ross, Chairman | Via Walbrook PR | |
| John Hawkins, Chief Financial Officer | | |
| | | |
| Liberum Capital Limited (NOMAD and Joint Broker) Phil Walker (Investment Banking) Richard Lindley (Investment Banking) Ben Cryer (Investment Banking) | +44 (0)20 3100 2000
| |
| | | |
| Allenby Capital Limited (Joint Broker) | +44 (0)20 3328 5656 | |
| James Reeve/George Payne (Corporate Finance) | | |
| Stefano Aquilino (Sales & Corporate Broking) | | |
| | | |
| Walbrook PR (Media & Investor Relations) | +44 (0)20 7933 8780 or reneuron@walbrookpr.com | |
| Paul McManus / Alice Woodings | +44 (0)7980 541 893 / +44 (0)7407 804 654 | |
About ReNeuron
ReNeuron has developed a proprietary stem cell-derived, exosome-based, drug delivery platform with customisable cellular targeting capabilities for the delivery of complex drug modalities.
Through the generation of several unique and scalable exosome producer cell lines, our CustomEX™ platform can be optimised for specific tissues targets and payloads leading to improvements in therapeutic outcome and a reduction in off-target effects. ReNeuron offers a delivery mechanism for a variety of payloads such as siRNA, mRNA, proteins, small molecules and genes. Through its conditionally immortalised induced pluripotent stem cell (iPSC) platform, the Company can make allogeneic tissue cells of choice and has the potential to produce exosomes with tissue specific targeting ability.
ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. For further information visit www.reneuron.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.